Abstract
Typical features of pneumococcal meningitis have been demonstrated in rats inoculated with Streptococcus pneumoniae. HU-211, a novel noncompetitive N- methyl-D-aspartate antagonist recently demonstrated to inhibit tumor necrosis factor-α production under various conditions, improves recovery in some experimental models of brain injury. The present study tested the efficacy of HU-211 in combination with antimicrobial therapy in reducing brain damage in experimental pneumococcal meningitis. S. pneumoniae-infected rats were treated with saline alone, ceftriaxone alone, or with a combination of ceftriaxone and HU-211 18 h after inoculation of the bacteria. Brain edema and blood-brain barrier impairment 48 h after infection were significantly (P < .05) reduced in rats treated with ceftriaxone-HU-211 compared with rats in other treatment groups. The results suggest that HU-211 when given concomitantly with antibiotics attenuates brain damage in the rat model of pneumococcal meningitis.
| Original language | English |
|---|---|
| Pages (from-to) | 735-738 |
| Number of pages | 4 |
| Journal | Journal of Infectious Diseases |
| Volume | 173 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1996 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver